Evidence map›Paper›PMID 33374358›Full record

ArticleInternational journal of molecular sciences2020

Tedizolid-Cyclodextrin System as Delayed-Release Drug Delivery with Antibacterial Activity.

Magdalena Paczkowska-Walendowska, Natalia Rosiak, Ewa Tykarska, Katarzyna Michalska, Anita Płazińska, Wojciech Płaziński, Daria Szymanowska, Judyta Cielecka-Piontek

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Outstanding Contributions to Aerosol Pulmonary Drug Delivery.Kona : powder science and technology in Japan · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Magdalena Paczkowska-WalendowskaDepartment of Pharmacognosy, Faculty of Pharmacy, Poznan University of Medical Sciences, Swiecickiego 4, 61-781 Poznan, Poland.ORCID 0000-0002-0418-9336
Natalia RosiakDepartment of Pharmacognosy, Faculty of Pharmacy, Poznan University of Medical Sciences, Swiecickiego 4, 61-781 Poznan, Poland.ORCID 0000-0003-4722-6413
Ewa TykarskaDepartment of Chemical Technology of Drugs, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznan, Poland.ORCID 0000-0001-9393-3536
Katarzyna MichalskaDepartment of Synthetic Drugs, National Medicines Institute, Chelmska 30/34, 00-725 Warsaw, Poland.
Anita PłazińskaDepartment of Biopharmacy, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4a, 20-093 Lublin, Poland.
Wojciech PłazińskiJerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences, Niezapominajek 8, 30-239 Krakow, Poland.
Daria SzymanowskaDepartment of Biotechnology and Food Microbiology, Poznan University of Life Sciences, Wojska Polskiego 48, 60-627 Poznan, Poland.ORCID 0000-0002-4665-1576
Judyta Cielecka-PiontekDepartment of Pharmacognosy, Faculty of Pharmacy, Poznan University of Medical Sciences, Swiecickiego 4, 61-781 Poznan, Poland.ORCID 0000-0003-0891-5419
Poznan University of Medical Sciences · PLJerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences · PLMedical University of Lublin · PLNarodowy Instytut Leków · PLUniversity of Life Sciences in Poznań · PL

Funding

National Science Centre 2015/17/N/NZ7/00937
6 · The paper itself

Abstract

Progressive increase in bacterial resistance has caused an urgent need to introduce new antibiotics, one of them being oxazolidinones with their representative tedizolid. Despite the broad spectrum of activity of the parent tedizolid, it is characterized by low water solubility, which limits its use. The combination of the active molecule with a multifunctional excipient, which is cyclodextrins, allows preservation of its pharmacological activity and modification of its physicochemical properties. Therefore, the aim of the study was to change the dissolution rate and permeability through the model membrane of tedizolid by formation of solid dispersions with a cyclodextrin. The research included identification of tedizolid-hydroxypropyl-β-cyclodextrin (tedizolid/HP-β-CD) inclusion complex by thermal method (Differential Scanning Colorimetry), spectroscopic methods (powder X-ray diffraction, Fourier-Transform Infrared spectroscopy), and molecular docking. The second part of the research concerned the physicochemical properties (dissolution and permeability) and the biological properties of the system in terms of its microbiological activity. An increase in the dissolution rate was observed in the presence of cyclodextrin, while maintaining a high permeation coefficient and high microbiological activity. The proposed approach is an opportunity to develop drug delivery systems used in the treatment of resistant bacterial infections, in which, in addition to modifying the physicochemical properties caused by cyclodextrin, we observe a favorable change in the pharmacological potential of the bioactives.

Indexed as

Drug Delivery Systems2-Hydroxypropyl-beta-cyclodextrinAnti-Bacterial Agentsbeta-CyclodextrinsCalorimetry, Differential ScanningCyclodextrinsDelayed-Action PreparationsDrug LiberationDrug Resistance, BacterialHydrogen-Ion ConcentrationMolecular Docking SimulationOxazolidinonesOxidative StressPermeabilityPowdersSolubility2-Hydroxypropyl-beta-cyclodextrinAnti-Bacterial Agentsbeta-CyclodextrinsCyclodextrinsDelayed-Action PreparationsOxazolidinonesPowderstedizolidTetrazolescyclodextrindissolutionpermeabilitytedizolid

Identifiers

PMID33374358
PMCPMC7795824
OpenAlexW3114676922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.